Skip to main content

Facilitating Collaborations to Develop Combination Investigational Cancer Therapies Workshop Summary (2012) / Chapter Skim
Currently Skimming:

References
Pages 97-100

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 97...
... :451–456. CEO Life Sciences Consortium and NCI (National Cancer Institute)
Read the entire page →
From page 98...
... 2010b. A national cancer clinical trials system for the 21st century: Reinvigorating the NCI Cooperative Group Program.
Read the entire page →
From page 99...
... 2011. Clinical combi nation of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in human Phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors.
Read the entire page →

Key Terms

  • accessed september
  • clinical oncology
  • cancer clinical
  • breast cancer
  • accessed august

  • clinical trials
  • cancer research
  • solid tumors
  • reviews drug
  • nature reviews

  • advanced solid
  • clinical trial
  • drug development
  • cancer institute
  • clinical cancer

  • personalizing ther
  • trastuzumab resistance
  • targeted therapy
  • sciences consortium
  • oral mtor

  • drug discovery
  • hutchinson cancer
  • human phase
  • antibody cixutumumab
  • procedural barriers

  • trial design
  • neoadjuvant chemo
  • immunotherapy drugs
  • tumor inhibition
  • intermittent dosing


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.